{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:07:07Z","timestamp":1756192027196},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s10620-014-3483-x","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T08:32:53Z","timestamp":1419237173000},"page":"1474-1481","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome"],"prefix":"10.1007","volume":"60","author":[{"given":"Cindy X.","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geetha","family":"Maddukuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Jaipaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gines","year":"1993","unstructured":"Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229\u2013236.","journal-title":"Gastroenterology"},{"key":"3483_CR2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","volume":"362","author":"P Gines","year":"2003","unstructured":"Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362:1819\u20131827.","journal-title":"Lancet"},{"key":"3483_CR3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690\u20131697.","journal-title":"Hepatology"},{"key":"3483_CR4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55\u201364.","journal-title":"Hepatology"},{"key":"3483_CR5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360\u20131368.","journal-title":"Gastroenterology"},{"key":"3483_CR6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941\u2013948.","journal-title":"Hepatology"},{"key":"3483_CR7","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Martin-Llahi","year":"2008","unstructured":"Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20131359.","journal-title":"Gastroenterology"},{"key":"3483_CR8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","volume":"36","author":"C Duvoux","year":"2002","unstructured":"Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374\u2013380.","journal-title":"Hepatology"},{"key":"3483_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(95)80273-8","volume":"22","author":"E Giostra","year":"1995","unstructured":"Giostra E, Ruedin P, Cunningham M, et al. Sustained effects of ornipressin in hepatorenal syndrome. J Hepatol. 1995;22:120\u2013121.","journal-title":"J Hepatol"},{"key":"3483_CR10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","volume":"51","author":"LL Gluud","year":"2010","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576\u2013584.","journal-title":"Hepatology"},{"key":"3483_CR11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10620-013-2899-z","volume":"59","author":"G Maddukuri","year":"2014","unstructured":"Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci. 2014;59:471\u2013481.","journal-title":"Dig Dis Sci"},{"key":"3483_CR12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499\u2013505.","journal-title":"J Hepatol"},{"key":"3483_CR13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293\u20131298.","journal-title":"J Hepatol"},{"key":"3483_CR14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","volume":"20","author":"TH Kiser","year":"2005","unstructured":"Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005;20:1813\u20131820.","journal-title":"Nephrol Dial Transplant"},{"key":"3483_CR15","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310\u20131318.","journal-title":"Gut"},{"key":"3483_CR16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","volume":"42","author":"L Ruiz-del-Arbol","year":"2005","unstructured":"Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439\u2013447.","journal-title":"Hepatology"},{"key":"3483_CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","volume":"51","author":"A Nazar","year":"2010","unstructured":"Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219\u2013226.","journal-title":"Hepatology"},{"key":"3483_CR18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.ajkd.2011.07.017","volume":"58","author":"JC Velez","year":"2011","unstructured":"Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58:928\u2013938.","journal-title":"Am J Kidney Dis"},{"key":"3483_CR19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.22395","volume":"17","author":"TD Boyer","year":"2011","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17:1328\u20131332.","journal-title":"Liver Transpl"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3483-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3483-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3483-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:44:22Z","timestamp":1559245462000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3483-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3483-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}